Norihisa Ishii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Norihisa Ishii has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Koichi Suzuki
Department of Clinical Laboratory Science, Faculty of Medical Technology, Teikyo University, Tokyo, Japan
13 shared publications Shuichi Mori
7 shared publicationsYuzuru Nagaoka
7 shared publicationsHiroshi Nakajima
6 shared publications- Kazue Nakanaga
Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan
6 shared publications - Yuko Ishido
Department of Mycobacteriology, Laboratory of Molecular Diagnostics, Leprosy Research Center, National Institute of Infectious Diseases, 4-2-1 Aoba-cho, Higashimurayama-shi 189-0002, Tokyo, Japan
5 shared publications
Latest Publications
- 1 May 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (2) , e5-e6
Self-genomic double-stranded DNA is a potential trigger of keratinocyte hyperproliferation in psoriasis
- 1 May 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (2) , e5-e6
Self-genomic double-stranded DNA is a potential trigger of keratinocyte hyperproliferation in psoriasis
- 1 January 2017
- Published by Japanese Leprosy Association in JAPANESE JOURNAL OF LEPROSY
- Vol. 86 (2) , 91-100
Guideline for clinical use of thalidomide for management of erythema nodosum leprosum in Japan
Treatment of erythema nodosum leprosum (ENL, type 2 lepra reaction) with thalidomide is an effective alternative to steroid therapy, but Ministry of Health, Labour and Welfare (Japan) has only approved thalidomide (Thaled® Capsule, Fujimoto Pharmaceutical Corp.) for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS®) 2008. Then thalidomide was approved for ENL in 2012 by Ministry of Health, Labour and Welfare. Use of thalidomide for patients with ENL has already been established by various studies in other countries, but limited experience in Japan has hindered application of this medication to domestic patients. This led us to devise a guideline on the usage of thalidomide to treat ENL in Japan. Based on TERMS®, we suggest that administration of thalidomide for ENL should be started at 50-100mg/day p. o. before going to bed and then the dose should be adjusted according to the patient’s symptoms, while not exceeding the maximum recommended dose of 300mg/day.
- 1 January 2017
- Published by Japanese Leprosy Association in JAPANESE JOURNAL OF LEPROSY
- Vol. 86 (2) , 91-100
Guideline for clinical use of thalidomide for management of erythema nodosum leprosum in Japan
Treatment of erythema nodosum leprosum (ENL, type 2 lepra reaction) with thalidomide is an effective alternative to steroid therapy, but Ministry of Health, Labour and Welfare (Japan) has only approved thalidomide (Thaled® Capsule, Fujimoto Pharmaceutical Corp.) for the treatment of multiple myeloma under the Thalidomide Education and Risk Management System (TERMS®) 2008. Then thalidomide was approved for ENL in 2012 by Ministry of Health, Labour and Welfare. Use of thalidomide for patients with ENL has already been established by various studies in other countries, but limited experience in Japan has hindered application of this medication to domestic patients. This led us to devise a guideline on the usage of thalidomide to treat ENL in Japan. Based on TERMS®, we suggest that administration of thalidomide for ENL should be started at 50-100mg/day p. o. before going to bed and then the dose should be adjusted according to the patient’s symptoms, while not exceeding the maximum recommended dose of 300mg/day.
- Open Access
- 20 December 2014
- Published by Springer Nature in BMC Immunology
- Vol. 15 (1) , 586
Rapid preparation of high-purity nuclear proteins from a small number of cultured cells for use in electrophoretic mobility shift assays
Highly purified nuclear protein is required when using an electrophoretic mobility shift assay (EMSA) to study transcription factors, e.g. nuclear factor-κB (NF-κB), a major transcription factor that regulates both innate and adaptive immune responses following infection. Although many protocols have been developed for nuclear protein extraction, they are not necessarily optimized for use in EMSA, often require a large number of cells and long processing times, and do not always result in complete separation of the nuclear and cytoplasmic fractions. We have developed a simple, rapid and cost-effective method to prepare highly purified nuclear proteins from a small number of both suspended and adherent cultured cells that yields nuclear proteins comparable to those prepared by a standard large-scale method. The efficiency of the method was demonstrated by using EMSA to show the successful detection, in multilple concurrent samples, of NF-κB activation upon tetradecanoyl phorbol acetate (TPA) stimulation. This method requires only a small number of cells and no specialized equipment. The steps have been simplified, resulting in a short processing time, which allows researchers to process multiple samples simultaneously and quickly. This method is especially optimized for use in EMSA, and may be useful for other applications that include proteomic analysis.
- 20 December 2014
- Published by Springer Nature in BMC Immunology
- Vol. 15 (1) , 586
Open AccessRapid preparation of high-purity nuclear proteins from a small number of cultured cells for use in electrophoretic mobility shift assays
Highly purified nuclear protein is required when using an electrophoretic mobility shift assay (EMSA) to study transcription factors, e.g. nuclear factor-κB (NF-κB), a major transcription factor that regulates both innate and adaptive immune responses following infection. Although many protocols have been developed for nuclear protein extraction, they are not necessarily optimized for use in EMSA, often require a large number of cells and long processing times, and do not always result in complete separation of the nuclear and cytoplasmic fractions. We have developed a simple, rapid and cost-effective method to prepare highly purified nuclear proteins from a small number of both suspended and adherent cultured cells that yields nuclear proteins comparable to those prepared by a standard large-scale method. The efficiency of the method was demonstrated by using EMSA to show the successful detection, in multilple concurrent samples, of NF-κB activation upon tetradecanoyl phorbol acetate (TPA) stimulation. This method requires only a small number of cells and no specialized equipment. The steps have been simplified, resulting in a short processing time, which allows researchers to process multiple samples simultaneously and quickly. This method is especially optimized for use in EMSA, and may be useful for other applications that include proteomic analysis.
- Open Access
- 21 July 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (7) , 12895-12912
Iodine Excess as an Environmental Risk Factor for Autoimmune Thyroid Disease
The global effort to prevent iodine deficiency disorders through iodine supplementation, such as universal salt iodization, has achieved impressive progress during the last few decades. However, iodine excess, due to extensive environmental iodine exposure in addition to poor monitoring, is currently a more frequent occurrence than iodine deficiency. Iodine excess is a precipitating environmental factor in the development of autoimmune thyroid disease. Excessive amounts of iodide have been linked to the development of autoimmune thyroiditis in humans and animals, while intrathyroidal depletion of iodine prevents disease in animal strains susceptible to severe thyroiditis. Although the mechanisms by which iodide induces thyroiditis are still unclear, several mechanisms have been proposed: (1) excess iodine induces the production of cytokines and chemokines that can recruit immunocompetent cells to the thyroid; (2) processing excess iodine in thyroid epithelial cells may result in elevated levels of oxidative stress, leading to harmful lipid oxidation and thyroid tissue injuries; and (3) iodine incorporation in the protein chain of thyroglobulin may augment the antigenicity of this molecule. This review will summarize the current knowledge regarding excess iodide as an environmental toxicant and relate it to the development of autoimmune thyroid disease.
- 21 July 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (7) , 12895-12912
Open AccessIodine Excess as an Environmental Risk Factor for Autoimmune Thyroid Disease
The global effort to prevent iodine deficiency disorders through iodine supplementation, such as universal salt iodization, has achieved impressive progress during the last few decades. However, iodine excess, due to extensive environmental iodine exposure in addition to poor monitoring, is currently a more frequent occurrence than iodine deficiency. Iodine excess is a precipitating environmental factor in the development of autoimmune thyroid disease. Excessive amounts of iodide have been linked to the development of autoimmune thyroiditis in humans and animals, while intrathyroidal depletion of iodine prevents disease in animal strains susceptible to severe thyroiditis. Although the mechanisms by which iodide induces thyroiditis are still unclear, several mechanisms have been proposed: (1) excess iodine induces the production of cytokines and chemokines that can recruit immunocompetent cells to the thyroid; (2) processing excess iodine in thyroid epithelial cells may result in elevated levels of oxidative stress, leading to harmful lipid oxidation and thyroid tissue injuries; and (3) iodine incorporation in the protein chain of thyroglobulin may augment the antigenicity of this molecule. This review will summarize the current knowledge regarding excess iodide as an environmental toxicant and relate it to the development of autoimmune thyroid disease.
- 18 June 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (8) , 771-772
Two cases of Buruli ulcer in Japanese brothers
- 18 June 2014
- Published by Wiley in The Journal of Dermatology
- Vol. 41 (8) , 771-772
Two cases of Buruli ulcer in Japanese brothers
- Open Access
Comprehensive Analysis of Prokaryotes in Environmental Water Using DNA Microarray Analysis and Whole Genome Amplification
The microflora in environmental water consists of a high density and diversity of bacterial species that form the foundation of the water ecosystem. Because the majority of these species cannot be cultured in vitro, a different approach is needed to identify prokaryotes in environmental water. A novel DNA microarray was developed as a simplified detection protocol. Multiple DNA probes were designed against each of the 97,927 sequences in the DNA Data Bank of Japan and mounted on a glass chip in duplicate. Evaluation of the microarray was performed using the DNA extracted from one liter of environmental water samples collected from seven sites in Japan. The extracted DNA was uniformly amplified using whole genome amplification (WGA), labeled with Cy3-conjugated 16S rRNA specific primers and hybridized to the microarray. The microarray successfully identified soil bacteria and environment-specific bacteria clusters. The DNA microarray described herein can be a useful tool in evaluating the diversity of prokaryotes and assessing environmental changes such as global warming.
Open AccessComprehensive Analysis of Prokaryotes in Environmental Water Using DNA Microarray Analysis and Whole Genome Amplification
The microflora in environmental water consists of a high density and diversity of bacterial species that form the foundation of the water ecosystem. Because the majority of these species cannot be cultured in vitro, a different approach is needed to identify prokaryotes in environmental water. A novel DNA microarray was developed as a simplified detection protocol. Multiple DNA probes were designed against each of the 97,927 sequences in the DNA Data Bank of Japan and mounted on a glass chip in duplicate. Evaluation of the microarray was performed using the DNA extracted from one liter of environmental water samples collected from seven sites in Japan. The extracted DNA was uniformly amplified using whole genome amplification (WGA), labeled with Cy3-conjugated 16S rRNA specific primers and hybridized to the microarray. The microarray successfully identified soil bacteria and environment-specific bacteria clusters. The DNA microarray described herein can be a useful tool in evaluating the diversity of prokaryotes and assessing environmental changes such as global warming.
- 26 September 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 39 (6) , 569-572
CutaneousMycobacterium massilienseinfection: A sporadic case in Japan
- 26 September 2011
- Published by Wiley in The Journal of Dermatology
- Vol. 39 (6) , 569-572
CutaneousMycobacterium massilienseinfection: A sporadic case in Japan
- 1 February 2011
- Vol. 80 (1) , 29-36
[Leprosy in a chimpanzee].
Leprosy is suspected to develop after a long period of latency following infection with Mycobacterium leprae (M. leprae) during infancy, but definitive proof has been lacking. We found a rare case of leprosy in a chimpanzee (Pan troglodytes) born in West Africa (Sierra Leone) and brought to Japan around 2 years of age. At 31, the ape started exhibiting pathognomic signs of leprosy. Pathological diagnosis, skin smear, serum anti-phenolic glycolipid-I (PGL-I) antibody, and by PCR analysis demonstrated lepromatous leprosy. Single-nucleotide polymorphism (SNP) analysis verified the West African origin of the bacilli. This occurrence suggests the possibility of leprosy being endemic among wild chimpanzees in West Africa, potentially posing a zoonotic risk.
- 1 February 2011
- Vol. 80 (1) , 29-36
[Leprosy in a chimpanzee].
Leprosy is suspected to develop after a long period of latency following infection with Mycobacterium leprae (M. leprae) during infancy, but definitive proof has been lacking. We found a rare case of leprosy in a chimpanzee (Pan troglodytes) born in West Africa (Sierra Leone) and brought to Japan around 2 years of age. At 31, the ape started exhibiting pathognomic signs of leprosy. Pathological diagnosis, skin smear, serum anti-phenolic glycolipid-I (PGL-I) antibody, and by PCR analysis demonstrated lepromatous leprosy. Single-nucleotide polymorphism (SNP) analysis verified the West African origin of the bacilli. This occurrence suggests the possibility of leprosy being endemic among wild chimpanzees in West Africa, potentially posing a zoonotic risk.
- 1 February 2011
- Vol. 80 (1) , 47-52
[History of Hansen's disease medical summer college].
- Open Access
- 1 January 2011
- Published by Japanese Leprosy Association in JAPANESE JOURNAL OF LEPROSY
- Vol. 80 (3) , 261-268
[Leprosy outpatient clinic in Aichi Prefecture, Japan].
Until the Japanese Leprosy Prevention Law was abolished in 1996, leprosy patients, regardless of their severity, had to be treated by accredited doctors. The majority of them had to be confined in a sanatorium to be treated, since only few hospitals/sanatoria had outpatient clinics for leprosy patients. This de facto confinement limited their occupational, social, financial, and family options, but no clear criteria/guidelines allowing discharge existed. The importance of leprosy outpatient clinics was almost never debated until 1962, when Tofu Association (a foundation established in 1952 to support the confined patients) and the National Suruga Sanatorium planned the opening of the clinic. This clinic looked after total of 4,977 patients until the abolishment of the Law. Since 1996, 349 persons consulted the clinic as of 2010. The importance of the continuation of these clinics is beyond dispute, even in low-endemic countries. However, the diminishing number of patients and demands in this country makes the management difficult. Thus, coordination with the local clinics and dermatologists is inevitable.
- 1 January 2011
- Published by Japanese Leprosy Association in JAPANESE JOURNAL OF LEPROSY
- Vol. 80 (3) , 261-268
Open Access[Leprosy outpatient clinic in Aichi Prefecture, Japan].
Until the Japanese Leprosy Prevention Law was abolished in 1996, leprosy patients, regardless of their severity, had to be treated by accredited doctors. The majority of them had to be confined in a sanatorium to be treated, since only few hospitals/sanatoria had outpatient clinics for leprosy patients. This de facto confinement limited their occupational, social, financial, and family options, but no clear criteria/guidelines allowing discharge existed. The importance of leprosy outpatient clinics was almost never debated until 1962, when Tofu Association (a foundation established in 1952 to support the confined patients) and the National Suruga Sanatorium planned the opening of the clinic. This clinic looked after total of 4,977 patients until the abolishment of the Law. Since 1996, 349 persons consulted the clinic as of 2010. The importance of the continuation of these clinics is beyond dispute, even in low-endemic countries. However, the diminishing number of patients and demands in this country makes the management difficult. Thus, coordination with the local clinics and dermatologists is inevitable.